Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva CEO Steps Down While An Integration Hangs In The Balance

Executive Summary

After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.


Related Content

Stockwatch: Limited Acquisition Headroom At Specialty Pharma
Stockwatch: Flat Is The New Black For Lilly And Sanofi
Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February
Teva Appoints New Global Generics Head Amid Massive Integration
Teva Hits Pause On Business Development, Even As Some Deals Stumble
Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
Teva CEO Vigodman Reveals A First Glimpse At His Strategy
Teva Director Vigodman’s Name Floated As New CEO


Related Companies